Safar Center for Resuscitation Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15260, USA.
J Neurotrauma. 2010 May;27(5):901-10. doi: 10.1089/neu.2009.1075.
We reported that adenosine A(1) receptor (A(1)AR) knockout (KO) mice develop lethal status epilepticus after experimental traumatic brain injury (TBI), which is not seen in wild-type (WT) mice. Studies in epilepsy, multiple sclerosis, and neuro-oncology suggest enhanced neuro-inflammation and/or neuronal death in A(1)AR KO. We hypothesized that A(1)AR deficiency exacerbates the microglial response and neuronal damage after TBI. A(1)AR KO and WT littermates were subjected to mild controlled cortical impact (3 m/sec; 0.5 mm depth) to left parietal cortex, an injury level below the acute seizure threshold in the KO. At 24 h or 7 days, mice were sacrificed and serial sections prepared. Iba-1 immunostaining was used to quantify microglia at 7 days. To assess neuronal injury, sections were stained with Fluoro-Jade C (FJC) at 24 h to evaluate neuronal death in the hippocampus and cresyl violet staining at 7 days to analyze cortical lesion volumes. We also studied the effects of adenosine receptor agonists and antagonists on (3)H-thymidine uptake (proliferation index) by BV-2 cells (immortalized mouse microglial). There was no neuronal death in CA1 or CA3 quantified by FJC. A(1)AR KO mice exhibited enhanced microglial response; specifically, Iba-1 + microglia were increased 20-50% more in A(1)AR KO versus WT in ipsilateral cortex, CA3, and thalamus, and contralateral cortex, CA1, and thalamus (p < 0.05). However, contusion and cortical volumes did not differ between KO and WT. Pharmacological studies in cultured BV-2 cells indicated that A(1)AR activation inhibits microglial proliferation. A(1)AR activation is an endogenous inhibitor of the microglial response to TBI, likely via inhibition of proliferation, and this may represent a therapeutic avenue to modulate microglia after TBI.
我们曾报道,腺嘌呤核苷酸 A1 受体(A1AR)敲除(KO)小鼠在实验性创伤性脑损伤(TBI)后会发展为致死性癫痫状态,而野生型(WT)小鼠则不会出现这种情况。在癫痫、多发性硬化症和神经肿瘤学的研究中表明,A1AR KO 小鼠的神经炎症和/或神经元死亡增强。我们假设 A1AR 缺失会加剧 TBI 后的小胶质细胞反应和神经元损伤。将 A1AR KO 和 WT 同窝仔鼠进行轻度控制性皮质撞击(3 m/sec;0.5 mm 深度),损伤位于 KO 急性惊厥阈值以下的左侧顶叶皮质。在 24 小时或 7 天时,处死小鼠并制备连续切片。在 7 天时用 Iba-1 免疫染色来定量小胶质细胞。为了评估神经元损伤,在 24 小时时用氟-金雀花碱 C(FJC)染色评估海马神经元死亡,在 7 天时用 Cresyl 紫染色分析皮质损伤体积。我们还研究了腺苷受体激动剂和拮抗剂对(3)H-胸腺嘧啶摄取(增殖指数)的影响,用 BV-2 细胞(永生化小鼠小胶质细胞)进行分析。FJC 未检测到 CA1 或 CA3 中的神经元死亡。A1AR KO 小鼠表现出增强的小胶质细胞反应;具体来说,在同侧皮质、CA3 和丘脑以及对侧皮质、CA1 和丘脑,A1AR KO 小鼠的 Iba-1+小胶质细胞比 WT 增加了 20-50%(p <0.05)。然而,KO 和 WT 之间的挫伤和皮质体积没有差异。在培养的 BV-2 细胞中的药理学研究表明,A1AR 激活抑制小胶质细胞增殖。A1AR 激活是 TBI 中小胶质细胞反应的内源性抑制剂,可能通过抑制增殖来实现,这可能代表了一种调节 TBI 后小胶质细胞的治疗途径。